Author pages are created from data sourced from our academic publisher partnerships and public sources.
OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection
- T. Louie, Judy Emery, Walter Krulicki, B. Byrne, M. Mah
- Medicine, Biology
- Antimicrobial Agents and Chemotherapy
- 27 October 2008
ABSTRACT During a 10-day treatment for Clostridium difficile infection, OPT-80 and vancomycin were comparably effective in reducing C. difficile counts. Bacteroides fragilis group counts appeared… Expand
Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
- T. Louie, K. Cannon, +4 authors Walter Krulicki
- Clinical infectious diseases : an official…
- 1 August 2012
The microflora-sparing properties of fidaxomicin were examined during the conduct of a randomized clinical trial comparing vancomycin 125 mg 4 times per day versus fidaxomicin 200 mg twice per day… Expand
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
Clostridium difficile infection (CDI) is the most common identifiable cause of diarrhoea in hospitalized patients. Current therapies rely on the administration of metronidazole or vancomycin, which… Expand